New mRNA vaccine targets Hard-to-Treat lymphoma in early trial
NCT ID NCT07334574
First seen Jan 12, 2026 · Last updated May 19, 2026 · Updated 23 times
Summary
This early-stage study tests a personalized mRNA vaccine (XP-006) for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The vaccine is custom-made to train the immune system to attack each patient's unique tumor. The main goal is to check safety and find the right dose, with a small group of 20 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.